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Exon 2 of the Bcl-x gene undergoes alternative
splicing in which the Bcl-xS splice variant
promotes apoptosis in contrast to the anti-apo-
ptotic splice variant Bcl-xL. In this study, the
regulation of the alternative splicing of pre-
mRNA of Bcl-x was examined in response to
emetine. Treatment of different types of cancer
cells with emetine dihydrochloride downregu-
lated the level of Bcl-xL mRNA with a concomi-
tant increase in the mRNA level of Bcl-xS in
a dose- and time-dependent manner. Pretreat-
ment with calyculin A, an inhibitor of protein
phosphatase 1 (PP1) and protein phosphatase
2A (PP2A), blocked emetine-induced alterna-
tive splicing in contrast to okadaic acid, a spe-
cific inhibitor of PP2A in cells, demonstrating a
PP1-mediated mechanism. Our finding on the
regulation of RNA splicing of members of the
Bcl-2 family in response to emetine presents
a potential target for cancer treatment.
INTRODUCTION
Alternative splicing occurs when the introns of a certain
pre-mRNA are excised in more than one way, producing
several possible mature mRNAs from one gene. Alterna-
tive pre-mRNA splicing is an essential mechanism for
generating protein diversity [1–4] according to different
regulatory programs. It is estimated that more than 60%
of human genes undergo alternative splicing, leading to
production of diversified functional isoforms [5]. Alterna-
tive splicing is precisely regulated. Aberrant splicing can
lead to human disorders such as growth hormone defi-
ciency, Frasier syndrome, Parkinson’s disease, cystic
fibrosis, retinitis pigmentosa, spinal muscular atrophy,
and myotonic dystrophy [6, 7].
Apoptosis, or programmed cell death, plays an impor-
tant role in normal tissue equilibrium by counterbalancing
cell production and cell loss. Cancers and neurodegener-
ative disorders often show a defective cell death program
[8], the former originating from too little apoptosis and the1386 Chemistry & Biology 14, 1386–1392, December 2007 ª20latter emerging from too much cell death. Deregulation of
the balance between proliferation and cell death repre-
sents a protumorigenic principle in human carcinogene-
sis. Alternative splicing plays a critical role in the control
of apoptosis. Several pre-mRNAs for cell death signals
are alternatively spliced, yielding isoforms with opposing
functions during programmed cell death [7].
One distinct example is the Bcl-x transcript, which is
alternatively spliced in exon 2 to produce the proapoptotic
Bcl-xS or the anti-apoptotic Bcl-xL [9]. The protein prod-
uct of the larger Bcl-xL functions as a repressor of pro-
grammed cell death [10], whereas the smaller Bcl-xS
encodes a protein that can accelerate cell death [11, 12].
Bcl-xL is highly expressed in several types of cancers,
and overexpression of Bcl-xL inhibits apoptosis and pro-
motes resistance to chemotherapy in tumors in vivo [13].
It has been found that Bcl-xL is overexpressed in high-
grade prostate cancer and associated with hormone
refractory phenotype [14]. Breast cancer also has a high
level of Bcl-xL that is correlated with an increased risk of
metastasis [15] and disallows apoptosis, gains resistance
against cytokines, alters the relationship between cells
and extracellular matrix, and probably renders a mecha-
nism for cells to adapt to a new environment [16]. In ovar-
ian cancers, Bcl-xL expression conferred resistance to
chemotherapy-induced apoptosis resulting from treat-
ment with cisplatin, paclitaxel, topotecan, and gemcita-
bine [17]. On the other hand, reduction of Bcl-xL protein
and/or increase of production of Bcl-xS by specific anti-
sense oligonucleotide (ISIS 16009) treatment or other
approaches enhanced the chemosensitivity or radiosensi-
tivity of colon cancer cells, breast cancer cells, HepG2
hepatoblastoma cells, and other tumor cell lines [18–23].
Because Bcl-xS overexpression can induce apoptosis in
tumoral cell lines [24], the ability to alter the Bcl-xL/Bcl-xS
ratio thus has promising therapeutic potential for cancer
treatment.
Numerous reports have demonstrated that Bcl-x alter-
native splicing can be regulated by small molecules such
as ceramide in cancer cells [25], as well as by other biolog-
ical molecules including IL-6, GM-CSF, amphetamine,
and TPA [26, 27]. To identify additional small molecules
that may be potentially used in cancer treatment by regu-
lating Bcl-x splicing, we performed RT-PCR experiments
in cells treated with 1040 Food and Drug Administration07 Elsevier Ltd All rights reserved
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Emetine Regulates Bcl-x SplicingFigure 1. Chemical Structures
(A) Emetine.
(B) Cycloheximide (CHX).(FDA)-approved drugs and compounds (National Institute
of Neurological Disorders and Stroke [NINDS] Custom
Collection, MicroSource Discovery Systems). We found
that emetine, a potent protein synthesis inhibitor in eukary-
otes [28], downregulated Bcl-xL and upregulated Bcl-xS.
We further demonstrate that this defined emetine function
is mediated by phosphorylation.
RESULTS
Emetine Regulates the Alternative Splicing
of Bcl-x Pre-mRNA
It has been hypothesized that modulation of the Bcl-xL/
Bcl-xS ratio by regulating alternative splicing of exon 2 in
the Bcl-x gene may have potential for cancer treatment.
To identify small molecules that regulate Bcl-x splicing,
we screened 1040 FDA-approved drugs and compounds
(NINDS Custom Collection, MicroSource Discovery Sys-
tems) using RT-PCR in C33A cells, a cervical cancer
line. We found that emetine (see chemical structure in Fig-
ure 1) reduced Bcl-xL mRNA with a concomitant increase
in Bcl-xS (Figures 2B and 2D). To further validate our find-
ings, C33A cells were treated overnight with various con-
centrations of emetine. There was a decrease in the ratio
of Bcl-xL/Bcl-xS from 9.6 to 2.6, 2.2, 1.8, and 1.5 with
emetine 0.1, 0.3, 1.0, and 10.0 mM, respectively (Figure 2B).
Interestingly, emetine did not alter splicing of tau, SMN,
and BACE1 genes, indicating its relative specificity for
Bcl-x splicing. Emetine (C29H40N2O4), the ipecac alkaloid,
is an amoebicidal agent that inhibits polypeptide chain
elongation in parasites [29–31]. Emetine is a potent protein
synthesis inhibitor in mammalian cells, plants, and yeastsChemistry & Biology 14, 1386–139[32]. Grollman has shown that emetine and cyclohexi-
mide, another protein synthesis inhibitor, have a similar
site and mode of action for inhibition of protein synthesis,
and his studies of the conformational, configurational, and
electrostatic properties of the emetine molecule suggest
that emetine and cycloheximide share certain structural
properties around two nitrogen atoms that are essential
for their activity (Figure 1) [32]. Consistent with this notion,
we also demonstrate that cycloheximide regulates alter-
native splicing of exon 2 in the Bcl-x gene (Figures 2C
and 2D). On the other hand, several other protein synthe-
sis inhibitors such as anisomycin and puromycin in the
NINDS collection of 1040 FDA-approved drugs and com-
pounds have no or little effect on splicing of exon 2 in the
Bcl-x gene, suggesting a relative specificity of emetine for
Bcl-x splicing. All experiments were repeated at least
three times.
Time andDosageDependence of Emetine onBcl-x
Splicing in Cancer Cells
To further validate whether emetine regulates exon 2 splic-
ing in the Bcl-x gene and to study whether regulation of
exon 2 splicing has potential relevance to cancer
therapy, we examined the effects of emetine on the pre-
mRNA processing of Bcl-x in several tumor cell lines. We
treated cells with different time durations and/or different
concentrations of emetine. Semiquantitative RT-PCR
was used to determine the effects of emetine. We found
that in MCF-7 (a breast cancer cell line) (Figures 3A and
3C) and PC3 (a prostate cancer cell line) cells (Figures 3B
and 3C), regulation of Bcl-x splicing is slightly more pro-
nounced. There was a decrease in the ratio of Bcl-xL/2, December 2007 ª2007 Elsevier Ltd All rights reserved 1387
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Emetine Regulates Bcl-x SplicingFigure 2. Emetine Regulates Bcl-x Splic-
ing in C33A Cells
C33A cells were treated with emetine. Total
RNA was extracted and analyzed by RT-PCR
for the alternative splicing of Bcl-x.
(A) Alternative splicing of exon 2 in the Bcl-x
gene produces the larger Bcl-xL and smaller
Bcl-xS.
(B) Decrease of Bcl-xL and increase of Bcl-xS
are correlated with emetine concentration.
(C) Cycloheximide (CHX) also regulates exon 2
splicing in the Bcl-x gene.
(D) Ratio of Bcl-xL/Bcl-xS. Each experiment
was repeated at least three times. Results
from all experiments consistently show that
emetine and cycloheximide (CHX) modulate
exon 2 splicing in the Bcl-x gene.Bcl-xS from 8.6 to 7.2, 5.1, 3.8, 3.3, and 3.0 in MCF-7 cells
and from 7.1 to 5.0, 4.8, 4.6, 3.3, and 3.1 in PC3 cells with
emetine 0.1, 0.3, 1.0, 3.0, and 10.0 mM, respectively
(Figure 3C). However, we see a more dramatic regulation
of Bcl-x splicing in lung cancer cell line A549 cells by eme-
tine (Figure 4). The effects of emetine on the pre-mRNA
Figure 3. Emetine Regulates Bcl-x Splicing in MCF-7 Breast
Cancer Cells and PC3 Prostate Cancer Cells
Total RNA was extracted from MCF-7 and PC3 cells that were treated
with emetine. Splicing of exon 2 in the Bcl-x gene was analyzed by
RT-PCR.
(A) RT-PCR results from MCF-7 cells treated with different concentra-
tions of emetine.
(B) RT-PCR results from PC3 cells treated with different concentra-
tions of emetine.
(C) Reduction of Bcl-xL and increase of Bcl-xS were observed and
quantified. All experiments were repeated at least three times and
consistently show that emetine regulates exon 2 splicing of the Bcl-x
gene in MCF-7 and PC3 cells.1388 Chemistry & Biology 14, 1386–1392, December 2007 ª20processing of Bcl-x in A549 cells were time course and
dosage dependent. For dosage-dependent study, A549
cells were treated overnight with various concentrations
of emetine. There was a decrease in the ratio of Bcl-xL/
Bcl-xS from 7.5 to 3.9, 2.9, 2.0, 1.5, and 1.2 with emetine
0.1, 0.3, 1.0, 3.0, and 10.0 mM, respectively (Figures 4A
and 4C). For time-course study, A549 cells were treated
with 1 mM emetine. There was a decrease in the ratio of
Figure 4. Emetine Regulates Bcl-x Splicing in A549 Lung
Cancer Cells
A549 cells were treated with emetine. Total RNA was extracted and
analyzed by RT-PCR for the alternative splicing of Bcl-x.
(A and C) Reduction of Bcl-xL and increase of Bcl-xS are correlated
with emetine concentration.
(B and D) Cells were treated with 1 mM emetine for different durations.
RT-PCR was carried out to quantify alternative splicing of Bcl-x. All
experiments were repeated at least three times.07 Elsevier Ltd All rights reserved
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Emetine Regulates Bcl-x SplicingFigure 5. Calyculin A but Not Okadaic
Acid Blocks Effects of Emetine on Bcl-x
Splicing
Cells were pretreated with either 5 mM calyculin
A, an inhibitor of both protein phosphatase 1
(PP1) and protein phosphatase 2A (PP2A), or
5 mM okadaic acid, a selective PP2A inhibitor,
and then exposed to 1.0 mM emetine for 24 hr.
RT-PCR was carried out. The results suggest
that PP1, not PP2A, mediates the effects of
emetine on the alternative splicing of Bcl-x.
(A) Effects of calyculin A in C33A cells.
(B) Effects of calyculin A in PC3 cells. All exper-
iments were repeated at least three times.
(C) Effects of calyculin A or okadaic acid on Bcl-x splicing mediated by emetine were quantified and plotted. Ratios of Bcl-xL/Bcl-xS in C33A cells:
no treatment, 12.0; with emetine, 4.5; with okadaic acid, 12.0; with emetine and okadaic acid, 5.8; with calyculin A, 12.0; with emetine and calyculin
A, 11.8. Ratios of Bcl-xL/Bcl-xS in PC3 cells: no treatment, 7.9; with emetine, 3.0; with okadaic acid, 7.0; with emetine and okadaic acid,
3.1; with calyculin A, 7.0; with emetine and calyculin A, 7.0. +: with emetine, okadaic acid, or calyculin A; 0: without emetine, okadaic acid, or
calyculin A.Bcl-xL/Bcl-xS from 7.2 to 3.3, 2.8, 1.3, 1.1, and 0.9 with the
duration of treatment of 6, 12, 24, 36, and 48 hr, respec-
tively (Figures 4B and 4D). However, because emetine is
a potent protein synthesis inhibitor, no synthesis of new
protein with exon 2b exclusion should be expected after
emetine treatment. Consistent with this notion, we ob-
served only a slight change of Bcl-xL/Bcl-xS ratio at the
protein level in A549 cells treated with emetine (see
Figure S1 in the Supplemental Data available with this
article online).
Emetine Exerts Its Effect on Bcl-x Splicing
via Protein Phosphatase 1
Previous studies show that ceramide affects splicing of
Bcl-x in a phosphorylation-dependent pathway. To exam-
ine whether emetine exerts the effects on Bcl-x splicing in
a similar manner, we treated C33A and PC3 cells with
phosphatase inhibitors calyculin A and okadaic acid.
We found that 5 mM calyculin A, an inhibitor of both
protein phosphatase 1 (PP1) and protein phosphatase
2A (PP2A), completely blocked the emetine effects on
Bcl-x alternative splicing in both C33A and PC3 cells
(Figure 5, compare +emetine with +emetine/calyculin A).
To establish whether PP1 or PP2A was the emetine-
responsive protein phosphatase that regulatesBcl-x alter-
native splicing, C33A and PC3 cells were pretreated for
1 hr with 5 mM okadaic acid, a selective PP2A inhibitor.
Pretreatment with okadaic acid had no effect on Bcl-x
alternative splicing (Figure 5, compare +emetine with
+emetine/okadaic acid). Taken together, these results
suggest that PP1 mediates the effects of emetine on the
alternative splicing of Bcl-x.
DISCUSSION
Bcl-x belongs to the Bcl-2 family and plays an important
role in apoptosis. Bcl-x produces anti-apoptotic Bcl-xL
and proapoptotic Bcl-xS via alternative splicing of exon
2 (Figure 2A). It has been suggested that the expression
of Bcl-xL in tumor cells is one of the important indicators
of chemotherapeutic efficacy because Bcl-xL protectsChemistry & Biology 14, 1386–139cells from a wide variety of apoptotic stimuli and confers
a multidrug resistance phenotype [33]. In contrast, the
smaller form, Bcl-xS, sensitizes cells to cell death in-
ducers. These data indicate that manipulating levels of
Bcl-xL and Bcl-xS proteins in tumors may provide a venue
for cancer treatment with a combination of chemothera-
peutic agents. Recent reports demonstrate that the alter-
native splicing of exon 2 in the Bcl-x gene can be altered
for this purpose [20]. For instance, modifying the ratio of
Bcl-xL to Bcl-xS in the cells with an antisense oligonu-
cleotide allows cells to be sensitized to undergo apoptosis
in response to ultraviolet B radiation and chemotherapeu-
tic agent treatment [34]. On the other hand, down-
regulation of Bcl-xL by RNA interference was shown to
suppress cell growth and induce apoptosis in human
esophageal cancer cells [35]. In chemotherapy-resistant
human colon cancer cells, Bcl-xL small interfering RNA
was found to suppress cell proliferation. Therefore,
Bcl- xL downregulation might provide a new target for
human chemotherapy-resistant cancer therapy [36].
Emetine is a potent inhibitor of protein synthesis in
mammalian cells, plants, and yeast [37]. It has been
shown that ()-emetine is an effective chemotherapeutic
agent by increasing the life span in tumor-bearing mice
[38, 39] and thus has possibilities for clinical advantage
[40]. To this end, emetine has been evaluated in phase II
clinical studies as a potential chemotherapeutic agent
for the treatment of solid tumors [41]. However, to our
knowledge, no previous study has explained the mecha-
nism responsible for the antitumor effect of emetine. In
this report, we demonstrate that emetine regulates alter-
native splicing of exon 2 in the Bcl-x gene, resulting in
more production of proapoptotic Bcl-xS with a concomi-
tant decrease in anti-apoptotic Bcl-xL, leading to our
speculation that regulating Bcl-x splicing is one of the un-
derlying mechanisms of the antitumor effect of emetine.
Because several other protein synthesis inhibitors includ-
ing anisomycin and puromycin in the 1040 FDA-approved
drugs/compounds did not alter the splicing of Bcl-x, we
reason that inhibition of new protein synthesis is unlikely
the mechanism of action for emetine on splicing. To2, December 2007 ª2007 Elsevier Ltd All rights reserved 1389
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investigate emetine analogs that do not inhibit protein syn-
thesis on the splicing of Bcl-x.
This defined mechanism was also shown to be depen-
dent on protein phosphatase 1 activation. This conclusion
was based on the use of the potent inhibitors of serine/
threonine-protein phosphatases, okadaic acid, and caly-
culin A. Calyculin A, which inhibits both PP1 and PP2A,
completely blocked emetine-induced alternative splicing
of Bcl-x, whereas okadaic acid, a specific inhibitor of
PP2A, had no effect on emetine-induced alternative splic-
ing of Bcl-x (Figure 5). This therefore implies that the
mechanism is dependent on PP1 activation. With the
demonstration of PP1 as an emetine-activated protein
phosphatase, potential PP1 substrates and mechanisms
regulated by PP1 became candidate targets for emetine
action. These findings are significant for several reasons.
First, this mechanism of emetine-induced alternative
splicing defines a mechanism of controlling the gene ex-
pression of proapoptotic factors in response to extra-
cellular inducing agents. Second, a specific and direct
mechanism mediated by an emetine-activated protein
phosphatase has been established. Interestingly, the
mechanistic action of emetine is similar to what has
been described for ceramide, a small molecule that also
induces, via alternative splicing, the expression of the
proapoptotic splice variant Bcl-xS, with a concomitant
loss in the anti-apoptotic splice variant Bcl-xL [25]. It ap-
pears that ceramide affects phosphorylation of SR pro-
teins, a conserved family of serine/arginine-rich (SR) splic-
ing factors which are involved in regulating splicing of
eukaryotic mRNA. Therefore, it would be important to ex-
amine whether and how emetine affects splicing factors
and whether ceramide is generated downstream of eme-
tine. Moreover, it is also possible that emetine selectively
affects the stability of either Bcl-xL or Bcl-xS mRNA, re-
sulting in the change of the Bcl-xL/Bcl-xS ratio. This
should be explored in the future. Finally, although cells
treated with emetine at low concentrations do not undergo
apoptosis, we observed that these cells are sensitized
to high concentrations of emetine and to other death
inducers (Figure S2), implying that regulation of the
Bcl-xL/Bcl-xS ratio may indeed affect cell survival.
In summary, we demonstrate that emetine reduces the
expression of the cell survival factor Bcl-xL and increases
the expression of proapoptotic factor Bcl-xS in MCF-7
breast cancer cells, PC3 prostate cancer cells, A549
lung cancer cells, and C33A cervical carcinoma cells. Fur-
ther study is needed to examine whether phosphorylation
of SR proteins is regulated by emetine-activated protein
phosphatase 1 and what the consequences are of the
dephosphorylation of SR proteins. Does this effect con-
tribute to the apoptosis process? What is the critical
percentage of Bcl-x splicing that determines chemothera-
peutic sensitivity? How much Bcl-xL needs to be spliced
to Bcl-xS in order to allow cells to become susceptible
to chemotherapy? These studies will have direct rele-
vance to chemotherapeutic sensitivity because specific
control of the alternative splicing of Bcl-x is linked to the1390 Chemistry & Biology 14, 1386–1392, December 2007 ª2sensitization of cells to chemotherapeutic agents, initiat-
ing a new target for anticancer treatment.
SIGNIFICANCE
Emetine is a crystalline alkaloid, C29H40N2O4, derived
from ipecac root. It is a potent protein synthesis inhib-
itor and is clinically used in the treatment of protozoan
infection. Emetine has shown promise as an antitumor
agent without bone marrow suppression.
In the present study, we have examined the effect of
emetine on the alternative pre-mRNA processing of
Bcl-x. We demonstrate that emetine downregulates
the levels ofBcl-xLmRNAwith a concomitant increase
in the mRNA levels of Bcl-xS in a dose-and time-
dependent manner. Mechanistically, emetine-induced
alternative splicing was dependent on the activation
of protein phosphatase 1. This conclusion is based
on the use of the potent inhibitors of serine/threo-
nine-protein phosphatases, okadaic acid, and caly-
culin A. To our knowledge, this is the first report on
the regulation of RNA splicing of members of the
Bcl-2 family in response to emetine. This significant
finding may have direct relevance to chemotherapeu-
tic sensitivity, giving rise to a new target for anticancer
therapies. Future study is needed to confirm whether
chemosensitivity is associated with increased Bcl-x
splicing and whether SR proteins are dephosphory-
lated by PP1-mediated action of emetine.
EXPERIMENTAL PROCEDURES
Compounds
All chemicals including emetine, cycloheximide, calyculin A, and
okadaic acid were purchased from Sigma.
Cell Culture
Human cervical carcinoma C33A cells were maintained in Dulbecco’s
modified Eagle’s media (DMEM) supplemented with 10% (v/v) fetal bo-
vine serum, L-glutamine, and penicillin-streptomycin. PC3 prostate
cancer cells were cultured in RPMI media supplemented with 10%
(v/v) fetal bovine serum, L-glutamine, and penicillin-streptomycin. Ad-
enocarcinoma 549 lung cancer cells were grown in DMEM/nutrient
mixture F-12 (Ham) supplemented with 10% (v/v) fetal bovine serum,
L-glutamine, and penicillin-streptomycin. Human breast cancer cells
MCF-7 and MCF-7/Adr were cultured in RPMI media supplemented
with 10% (v/v) fetal bovine serum, L-glutamine, and penicillin-strepto-
mycin. All cells were maintained at less than 80% confluence under
standard incubator conditions.
Emetine Treatment
Emetine dihydrochloride hydrate with the stock solution concentration
of 100 mM was used. Twenty-four hours prior to emetine treatment,
cells were plated in 2 ml of medium in 6-well plates at a density of
200,000 cells/well. The cells were treated with different concentrations
of emetine for 24 hr for dosage-dependence study. For time-course
experiments, cells were treated with 1.0 mM emetine for various
durations.
Protein Phosphatase Inhibitor Treatment
Cells were pretreated with calyculin A or okadaic acid for 1 hr. The
media were removed. Fresh regular media with emetine were added007 Elsevier Ltd All rights reserved
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examine Bcl-x splicing.
Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was extracted from cultured cells using Trizol reagent (Invi-
trogen) according to the manufacturer’s instructions. Reverse tran-
scription was carried out with 1 mg of total RNA using Improm II reverse
transcriptase (Promega) and oligo (dT) as the priming agent. After 1 hr
incubation at 42C, the reactions were terminated by heating at 70C
for 15 min. To analyze alternative splicing of exon 2 in the Bcl-x gene,
an upstream 50 primer toBcl-x (50-GAGGCAGGCGACGAGTTTGAA-30)
and a downstream 30 primer (50-TGGGAGGGTAGAGTGGATGGT-30)
were used for PCR amplification (32 cycles, 94C, 30 s; 55C, 30 s;
72C, 1 min) with Choice Taq Blue Mastermix (Denville). PCR products
were separated and analyzed on agarose gels.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.chembiol.com/cgi/content/full/14/12/
1386/DC1/.
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